Method for evaluating estrogen-like activity

By comparing transcription levels of specific genes using RNA-seq, the method addresses the reliability issues in estrogen-like activity evaluation, offering a more accurate assessment of estrogen-like activity in cells.

JP7870941B2Active Publication Date: 2026-06-08学校法人中村产业学园
View PDF 6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
学校法人中村产业学园
Filing Date
2022-03-14
Publication Date
2026-06-08

AI Technical Summary

Technical Problem

Existing methods for evaluating estrogen-like activity within cells lack reliability and accuracy, particularly in distinguishing between estrogen-induced and estrogen-like substance-induced activities.

Method used

A method involving the comparison of transcription levels of a predetermined gene group, including LINC02593, PDLIM3, RAP1GAP, and others, using RNA-seq to evaluate estrogen-like activity, ensuring genes with low coefficient of variation are selected for reliable evaluation.

Benefits of technology

This method provides a more reliable evaluation of estrogen-like activity by utilizing genes with low transcription variability, enhancing the accuracy and reliability of estrogen-like activity assessment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007870941000001
    Figure 0007870941000001
  • Figure 0007870941000002
    Figure 0007870941000002
  • Figure 0007870941000003
    Figure 0007870941000003
Patent Text Reader

Abstract

To provide a method for evaluating estrogenic activity, which can evaluate intracellular estrogen activity and estrogen-like activity more reliably than conventional methods.SOLUTION: The present invention provides a method for evaluating estrogenic activity of a test substance by comparing transcription levels in a predetermined gene group between cells treated with the test substance and untreated cells (control), wherein the predetermined gene group includes LINC02593, PDLIM3, RAP1GAP, ACOX2, B4GALT1, TMPRSS3, MATN2, SUSD3, FDFT1, ZNF521, FRY, BARX2, IL20, CTSD, CSTA, DOK7, CYP1A1, LOXL2, RAPGEFL1, PKIB, CCDC68, GATA4, SPOCD1, CRISP3, IGSF1, RAB26, EGR3, SRGAP3, SYNE1, and INSYN1.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art